According to The New York Times, artificial intelligence has been used to help develop a drug candidate called rentosertib, originally designed to treat a rare lung condition. The drug’s maker now reports that early data indicates rentosertib also appears to reduce biological hallmarks of aging.
The development represents an intersection of AI-driven drug discovery and aging research. While rentosertib was initially created to address a specific rare lung disease, the company behind the drug says preliminary findings suggest it may have broader anti-aging properties. The drug candidate was developed with the assistance of artificial intelligence technologies, which are increasingly being deployed in pharmaceutical research to identify and optimize potential therapeutic compounds.
The company’s claims about the drug’s effects on aging biomarkers come from early-stage data, though the specific details of these findings were not elaborated in the report. The use of AI in drug development has accelerated in recent years, with the technology helping researchers identify promising drug candidates more quickly than traditional methods.